## SEC Form 5

## FORM 5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Form 3 Holdings Reported.

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OMB APPROVAL
OMB Number: 3235-0362
Estimated average burden

Estimated average burden hours per response: 1.0

Form 4 Transac	tions Reported.	Filed	pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940				
1. Name and Address of Reporting Person* HENSON HEIDI			2. Issuer Name <b>and</b> Ticker or Trading Symbol Kura Oncology, Inc. [KURA]	(Check	tionship of Reporting Pe all applicable) Director Officer (give title	on(s) to Issuer 10% Owner Other (specify	
(Last) (First) (Middle) KURA ONCOLOGY, INC. 11119 N. TORREY PINES ROAD, SUITE 125		<b>、</b> ,	3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 12/31/2016	X	below) Chief Financia	below)	
(Street) LA JOLLA (City)	CA (State)	92037 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	ridual or Joint/Group Fili Form filed by One Re Form filed by More the Person	porting Person	

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned at end of	6. Ownership Form: Direct (D) or	7. Nature of Indirect Beneficial Ownership
				Amount	(A) or (D)	Price	Issuer's Fiscal Year (Instr. 3 and 4)	Indirect (I) (Instr. 4)	(Instr. 4)
Common Stock	11/11/2015		G <sup>(1)</sup>	3,000	D	\$0.00	247,596	D	
Common Stock	12/13/2016		<b>G</b> <sup>(1)</sup>	2,596	D	\$0.00	245,000	D	

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	(0.3., parte, care, concertance, concertance)													
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	of Derive Secur Acqui (A) or Dispo of (D) (Instr.	5. Number of Expiration Date Derivatives Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Amoun Securit Underly Derivat	7. Title and 8. Price Amount of Deriva Securities Securi Underlying (Instr. 3 and 4)		tive derivative ty Securities	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. This is a bona fide gift transaction exempt under Section 16(b). This transaction did not involve the sale of securities.

#### **Remarks:**

#### <u>Heidi Henson</u>

02/03/2017 Person Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.